1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
69BB09CF4F673F56900258AF50024B6FB
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/establishing-eu-standards-field-medical-performance-excellence
18
19
2034.236.191.0
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Medical Affairs » Field Medical Excellence

Establishing EU Standards for Field Medical Performance Excellence

ID: POP-375


Features:

10 Info Graphics

31 Data Graphics

610+ Metrics

18 Narratives


Pages: 47


Published: 2024


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Improving the performance of field medical teams is crucial for biopharma manufacturers seeking to maintain a competitive edge globally. But the European market, with its diverse regulations and preferences across individual countries, adds layers of complexity as manufacturers seek to enhance the capabilities and impact of their field medical teams.

Best Practices, LLC conducted benchmarking research tailored for the European market, aiming to aid Field Medical leaders in crafting a robust framework for excellence and consistent performance measurement across markets. This report delivers strategic insights to enrich KOL interactions, evaluate MSL performance, and strategically align staffing footprints. By addressing these critical topics, our research equips Field Medical leaders with the necessary knowledge and tactics to drive field medical performance excellence across Europe.

Leveraging a robust dataset,
the report further provides segmented insights at the country level, offering valuable benchmarks for the UK, France, Italy, Spain, Germany, and other EU markets.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Chemical; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; AstraZeneca; Bayer; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Clovis Oncology; CSL Behring; Curis; Daiichi Sankyo; Dermavant Sciences; Dompé; Eisai; Eurofarma; Exact Sciences; Galapagos; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline ; Grünenthal; Horizon Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Kyowa Kirin; Lundbeck; Merck; Merck KGaA; Merus; Novartis; Novo Nordisk; OM Pharma; Orchard Therapeutics; Pfizer; Radius Health; Inc.; Sanofi; Seres Therapeutics; Servier; Sunovion; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma; Ultragenyx; Vertex Pharmaceuticals

Study Snapshot

This report provides benchmarks and insights specific to Europe. The data from this study is drawn from a larger global pool of field leaders, featuring 448 survey responses from 100+ biopharma manufacturers worldwide. The data is meticulously segmented at the region and country level to provide nuanced insights.

Best Practices, LLC also leveraged its propriety Field Medical Excellence database to provide additional benchmarks tailored to align with diverse portfolio considerations.

Key topics covered in this report include:

  • Effective Field Performance Metrics in Europe
  • Field Medical Excellence Framework
  • Target and Engagement Levels of KOLs in Europe
  • Average MSL Time Spent in KOL Interactions and on Internal Activities
  • Europe Field Medical Staffing Footprint
  • Key Lessons Learned for Measuring MSL Impact in Europe

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • EU Engagement Mix: EU engagement includes a mix of 58% KOLs, 29% HCPs, 4% payers and 4% other stakeholders.
  • Time Allocation for External, Internal & Logistics Activities: EU MSLs allocate 59% of their time to external engagement, contrasting with 18% dedicated to internal support activities. Notably, MSLs in Germany and Spain allocate the highest percentage of their time (60%) to external engagement, underscoring the emphasis on external interactions in these markets.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Executive Summary: Laying the Foundation for Global Field Medical Performance Standards & ExpectationsPg. 3-17
II.
Europe: Region-level benchmarksPg. 18-33
Country-level benchmarksPg. 34-46
III.
About Best Practices, LLCPg. 47

    List of Charts & Exhibits

    I. Executive Summary: Laying the Foundation for Global Field Medical Performance Standards & Expectations

    • Overview of business objectives and research methodology
    • Regions covered in this benchmark study
    • Participating benchmark companies
    • Global benchmarking findings: Quick takeaways and recommendations
    • Summary of regional data: Europe market
    • Most effective and utilized field metrics for assessing and demonstrating the value of MSLs
    • Defining “monthly interactions”
    • Distinguishing an "actionable" insight from other kinds of insights
    • Definitions of "actionable insights" from the field
      Developing a global framework for excellence in field medical engagement
    • Metrics to assess MSL performance
    • Lessons learned around MSL time allocation in field and on external activities

    II. Europe:

    A. Region-level benchmarks

    • Average total panel size supported by an individual MSL in Europe
    • Average number of monthly KOL/HCP and F2F meetings in Europe
    • MSL’s average time spent per thought leader interaction in Europe
    • Value assigned to each interaction type on the MSL scorecard – Europe
    • Key metrics for evaluating and demonstrating MSL value in Europe
    • Engagement metrics for non-tiered KOLs in Europe
    • Average annual field presence of MSLs in Europe
    • MSL time allocation on external, internal and logistics activities in Europe
    • Weekly MSL time allocation across activity streams in Europe
    • MSL engagement mix in Europe
    • Average number of field staff members in Europe
    • Span of control: MSLs per MSL manager in Europe
    • Voices from the field: Key lessons learned for measuring MSL impact in Europe

    B. Country-level benchmarks

    • Average number of tiered vs. non-tiered KOLs per MSL in UK, France, Italy, Spain, Germany, and Mid-sized EU market (composite response)
    • Monthly KOL and F2F interactions in UK, France, Italy, Spain, Germany, and Mid-sized EU market (composite response)
    • MSL’s average time spent in each thought leader interaction in UK, France, Italy, Spain, Germany, and Mid-sized EU market (composite response)
    • Weighting criteria for various interaction types on the MSL scorecard – UK, France, Italy, Spain, Germany, and Mid-sized EU market (composite response)
    • Metrics for engaging non-tiered KOLs in UK, France, Italy, Spain, Germany, and Mid-sized EU market (composite response)
    • Average MSL time in the field (days per year) in UK, France, Italy, Spain, Germany, and Mid-sized EU market (composite response)
    • Percentage of MSL time spent on external, internal and logistics activities in UK, France, Italy, Spain, Germany, and Mid-sized EU market (composite response)
    • Weekly MSL time allocation on each activity stream in UK, France, Italy, Spain, Germany, and Mid-sized EU market (composite response)
    • Percentage of overall targets that can be classified as KOLs, HCPs, payers or other external stakeholders in UK, France, Italy, Spain, Germany, and Mid-sized EU market (composite response)
    • Average field medical team size – UK, France, Italy, Spain, Germany, and Mid-sized EU market (composite response)
    • Span of control: Number of MSLs per MSL manager in UK, France, Italy, Spain, Germany, and Mid-sized EU market (composite response)